28.93 +0.57 +2.03%
01:38:15 PM BTT

On Wednesday morning 05/15/2024 the Pfizer Inc. share started trading at the price of $28.37. Compared to the closing price on Tuesday 05/14/2024 on BTT of $28.36, this is a gain of 0.05%. There are 5.67 B shares outstanding in Pfizer Inc., which values the company at $161.10 B.
Is Pfizer stock a Buy, Sell or Hold? Pfizer stock has received a consensus rating of hold. The average rating score is A2 and is based on 28 buy ratings, 38 hold ratings, and 0 sell ratings.
What was the 52-week low for Pfizer stock? The low in the last 52 weeks of Pfizer stock was 25.21. According to the current price, Pfizer is 114.76% away from the 52-week low.
What was the 52-week high for Pfizer stock? The high in the last 52 weeks of Pfizer stock was 40.36. According to the current price, Pfizer is 71.68% away from the 52-week high.
What are analysts forecasts for Pfizer stock? The 66 analysts offering price forecasts for Pfizer have a median target of 48.00, with a high estimate of 75.00 and a low estimate of 27.00. The median estimate represents a 60.27 difference from the last price of 28.93.

Pfizer Stock Snapshot

28.92
Bid
2,371.00
Bid Size
28.93
Ask
2,036.00
Ask Size
5/15/2024
Date
1:38 PM
Time
838,823.00
Volume
28.36
Prev. Close
28.37
Open
161.10 B
Market Cap
5.67 B
Number of Shares
28.37
Day Low
28.98
Day High
28.93
25.21
52 Week Low
40.36
52 Week High
28.93
6.02
Dividend Yield
15.65
P/E Ratio
99.96
Free Float in %
2.34
EPS 2024
2.56
Cash Flow per Share

Historical Prices for Pfizer

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Pfizer Analyst Data

Total Analysts: 66
Buy Ratings: 28 Neutral Ratings: 38 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 27.00 Median: 48.00 Highest: 75.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Pfizer Analyst Opinions

Date Analyst Rating Price
05/02/24 Morgan Stanley
Maintained Hold $29
05/02/24 BMO Capital Markets
Maintained Buy $36
04/18/24 Cantor Fitzgerald
Maintained Buy $45
04/15/24 Cantor Fitzgerald
Maintained Buy $45
04/05/24 Cantor Fitzgerald
Maintained Buy $45
04/01/24 Cantor Fitzgerald
Maintained Buy $45
03/22/24 Argus Research Company
Downgraded to Hold
03/04/24 Cantor Fitzgerald
Maintained Buy $45
03/01/24 Cantor Fitzgerald
Maintained Buy $45
02/23/24 Guggenheim
Maintained Buy $36
01/31/24 Cantor Fitzgerald
Maintained Buy $45
01/09/24 Cantor Fitzgerald
Maintained Buy $45
12/14/23 UBS
Maintained Hold $27
12/14/23 Barclays Capital
Maintained Hold $28
11/20/23 Cantor Fitzgerald
Maintained Buy $75
11/01/23 Barclays Capital
Maintained Hold $34
11/01/23 Morgan Stanley
Maintained Hold $37
10/20/23 UBS
Maintained Hold $34
10/17/23 Morgan Stanley
Maintained Hold $39
10/16/23 BMO Capital Markets
Maintained Buy $33
10/16/23 Citigroup Corp.
Maintained Hold $35
10/16/23 J.P. Morgan
Maintained Hold $34
10/16/23 Wells Fargo & Co
Maintained Hold $35
10/06/23 J.P. Morgan
Maintained Hold $36
10/02/23 Cantor Fitzgerald
Maintained Buy $75
09/18/23 Cantor Fitzgerald
Maintained Buy $75
09/05/23 Cantor Fitzgerald
Maintained Buy $75
08/30/23 Cantor Fitzgerald
Maintained Buy $75
08/22/23 Cantor Fitzgerald
Maintained Buy $75
08/02/23 Morgan Stanley
Maintained Hold $40
08/02/23 BMO Capital Markets
Maintained Buy $44
07/21/23 Morgan Stanley
Maintained Hold $42
07/11/23 Morgan Stanley
Maintained Hold $43
07/11/23 Barclays Capital
Maintained Hold $38
06/29/23 Credit Suisse
Downgraded to Hold $40
06/22/23 Cantor Fitzgerald
Maintained Buy $75
05/17/23 Cantor Fitzgerald
Maintained Buy $75
05/11/23 Daiwa Securities
Downgraded to Hold $38
05/03/23 Credit Suisse
Maintained Buy $47
05/03/23 Barclays Capital
Maintained Hold $40
04/21/23 Bank of America Merrill Lynch
Maintained Hold $45
04/12/23 Barclays Capital
Maintained Hold $43
04/10/23 Morgan Stanley
Maintained Hold $44
03/17/23 Wells Fargo & Co
Maintained Hold $44
02/07/23 Daiwa Securities
Upgraded to Buy $51
02/01/23 Morgan Stanley
Maintained Hold $45
02/01/23 Cantor Fitzgerald
Maintained Buy $75
02/01/23 Credit Suisse
Maintained Buy $50
02/01/23 BMO Capital Markets
Maintained Buy $53
02/01/23 Barclays Capital
Maintained Hold $44

Pfizer Estimates* in USD

  2024 2025 2026 2027 2028
Revenue - - - - -
Dividend - - - - 1.76
Dividend Yield (in %) 6.02 % 6.15 % 6.19 % 6.26 % 6.19 %
EPS 2.34 - - - -
P/E Ratio 12.17 10.29 9.77 9.17 9.53
EBIT - - - - -
EBITDA - - - - -
Net Profit 13,352 15,425 16,158 17,422 16,717
Net Profit Adjusted 13,352 15,571 16,438 17,422 16,717
Pre-Tax Profit - - - - -
Net Profit (Adjusted) - - - 12,580 11,780
EPS (Non-GAAP) ex. SOE 2.34 - - - -
EPS (GAAP) - - - - -
Gross Income - - - - -
Cash Flow from Investing - - - - -
Cash Flow from Operations - - - - -
Cash Flow from Financing - - - - -
Cash Flow per Share 2.56 2.90 2.90 2.66 -
Free Cash Flow 10,265 12,478 14,187 12,915 -
Free Cash Flow per Share 1.98 2.27 2.57 - -
Book Value per Share - - - - 16.31
Net Debt 58,205 54,521 49,685 57,197 -
Research & Development Exp. - - - - -
Capital Expenditure - - - - -
Selling, General & Admin. Exp. - - - - -
Shareholder’s Equity 90,065 90,966 92,806 100,768 111,986
Total Assets - - - - -
  Previous Quarter
ending 03/31/24
Current Quarter Next Quarter Current Year Next Year
Earnings Estimates
No. of Analysts 15 - - 21 -
Average Estimate 0.516 USD - - 2.336 USD -
Year Ago 1.230 USD - - 1.840 USD -
Publish Date 5/1/2024 - - - -
Revenue Estimates
No. of Analysts 15 - - - -
Average Estimate 13,874 USD - - - -
Year Ago 18,282 USD - - - -
Publish Date 5/1/2024 - - - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Pfizer Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
BOSHOFF CHRISTOFFEL 02/27/2024 4,150.00 156,007.00 27.04 Sell No
BOSHOFF CHRISTOFFEL 02/27/2024 11,510.00 160,157.00 n/a Buy No
DAMICO JENNIFER B. 02/26/2024 5,113.00 13,495.00 n/a Buy No
de Germay Alexandre 02/26/2024 74,377.00 74,377.00 n/a Buy No
McDermott Michael 02/25/2024 6,063.00 75,463.00 27.18 Sell No
McDermott Michael 02/24/2024 2,992.00 81,526.00 27.76 Sell No
DAMICO JENNIFER B. 02/24/2024 1,386.00 8,382.00 27.76 Sell No
DAMICO JENNIFER B. 02/23/2024 354.00 9,768.00 27.76 Sell No
McDermott Michael 02/22/2024 10,031.00 84,518.00 27.37 Sell No
McDermott Michael 02/22/2024 859.00 94,549.00 27.76 Sell No
SUSMAN SALLY 02/22/2024 51,589.00 161,611.00 27.37 Sell No
SUSMAN SALLY 02/22/2024 4,948.00 213,200.00 27.76 Sell No
BOURLA ALBERT 02/22/2024 103,178.00 327,739.00 27.37 Sell No
BOURLA ALBERT 02/22/2024 8,831.00 430,917.00 27.76 Sell No
Dolsten Mikael 02/22/2024 24,822.00 343,166.00 27.76 Sell No
DAMICO JENNIFER B. 02/22/2024 7,881.00 10,122.00 27.37 Sell No
DAMICO JENNIFER B. 02/22/2024 774.00 18,003.00 27.76 Sell No
DAMICO JENNIFER B. 02/22/2024 451.00 18,777.00 27.76 Sell No
JOHNSON RADY A 02/22/2024 23,788.00 97,153.00 27.37 Sell No
JOHNSON RADY A 02/22/2024 2,132.00 120,941.00 27.76 Sell No
McDermott Michael 02/22/2024 12,412.00 95,408.00 27.34 Buy No
SUSMAN SALLY 02/22/2024 63,837.00 218,148.00 27.34 Buy No
BOURLA ALBERT 02/22/2024 127,674.00 439,748.00 27.34 Buy No
DAMICO JENNIFER B. 02/22/2024 9,752.00 19,228.00 27.34 Buy No
JOHNSON RADY A 02/22/2024 29,436.00 123,073.00 27.34 Buy No

Pfizer Dividend Calendar

Date Name Dividend *yield Currency
2023 Pfizer Inc. 1.65 5.73 USD
2022 Pfizer Inc. 1.61 3.14 USD
2021 Pfizer Inc. 1.57 2.66 USD
2020 Pfizer Inc. 1.53 4.16 USD
2019 Pfizer Inc. 1.46 3.73 USD
2018 Pfizer Inc. 1.38 3.16 USD
2017 Pfizer Inc. 1.30 3.59 USD
2016 Pfizer Inc. 1.22 3.76 USD
2015 Pfizer Inc. 1.14 3.53 USD
2015 Pfizer Inc. 1.12 3.47 USD
2014 Pfizer Inc. 1.04 3.34 USD
2014 Pfizer Inc. 1.06 3.40 USD
2013 Pfizer Inc. 0.98 3.20 USD
2013 Pfizer Inc. 0.96 3.13 USD
2012 Pfizer Inc. 0.88 3.51 USD
2012 Pfizer Inc. 0.90 3.59 USD
2011 Pfizer Inc. 0.80 3.70 USD
2011 Pfizer Inc. 0.82 3.79 USD
2010 Pfizer Inc. 0.72 4.11 USD
2010 Pfizer Inc. 0.74 4.23 USD
2009 Pfizer Inc. 0.66 3.63 USD
2009 Pfizer Inc. 0.80 4.40 USD
2008 Pfizer Inc. 1.28 7.23 USD
2007 Pfizer Inc. 1.16 5.10 USD
2006 Pfizer Inc. 0.96 3.71 USD
2005 Pfizer Inc. 0.76 3.26 USD
2004 Pfizer Inc. 0.68 2.53 USD
2003 Pfizer Inc. 0.60 1.70 USD
2002 Pfizer Inc. 0.52 1.70 USD
2001 Pfizer Inc. 0.44 1.10 USD
2000 Pfizer Inc. 0.36 0.78 USD
1999 Pfizer Inc. 0.31 USD
*Yield of the Respective Date

Pfizer Inc. Calendar

Event Estimate Info Date
Earnings Report - Q2 2024 Earnings Release 07/30/2024
Earnings Report - Q3 2024 Earnings Release 10/29/2024
Earnings Report - Q4 2024 Earnings Release 02/04/2025
Earnings Report - Q1 2025 Earnings Release 05/06/2025

Pfizer Inc. Past Events

Event Actual EPS Info Date
Earnings Report 0.820 USD Q1 2024 Earnings Release 05/01/2024
Annual General Meeting - Annual General Meeting 04/25/2024
Press Conference - - 01/30/2024
Press Conference - - 10/31/2023
Press Conference - - 08/01/2023

Pfizer Profile

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
6
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Pfizer Shareholder

Owner in %
Freefloat 99.96
The Vanguard Group, Inc. 8.97
Vanguard Group, Inc. (Subfiler) 8.54
SSgA Funds Management, Inc. 5.10
State Street Corp. 5.09
Wellington Management Co. LLP 4.24
Vanguard Total Stock Market ETF 3.14
Capital Research & Management Co. (World Investors) 3.07
BlackRock Fund Advisors 2.78
Vanguard 500 Index Fund 2.52
BlackRock Institutional Trust Co. NA 2.20
Charles Schwab Investment Management, Inc. 2.16
Geode Capital Management LLC 2.01
Schwab US Dividend Equity ETF 1.41
Norges Bank (13F) 1.31
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Pfizer Management

Name Job
Albert Bourla Chairman & Chief Executive Officer
Aamir Malik Chief Commercial Officer-US & Executive VP
Sally Susman Chief Corporate Affairs Officer & Executive VP
Roger D. Dansey Chief Development Officer-Oncology
David M. Denton Chief Financial Officer & Executive Vice President
Michael McDermott Chief Global Supply Officer & Executive VP
Alexandre de Germay Chief International Commercial Officer & EVP
Christopher J. Stevo Chief Investor Relations Officer & Senior VP
Maria Rivas Chief Medical Affairs Officer
Aida Habtezion Chief Medical Officer & Head-Worldwide Medical
Luis Jodar Chief Medical Officer-Vaccines & Senior VP
Chris Boshoff Chief Oncology Officer & Executive Vice President
Payal Sahni Becher Chief People Experience Officer & Executive VP
Patrice Ettinger Chief Privacy Offucer
Jeff Settleman Co-Chief Scientific Officer
Mikael Dolsten Co-Chief Scientific Officer & President-Research
Rady A. Johnson EVP, Chief Compliance, Quality & Risk Officer
Denis Patrick Executive Director & Vice President-WRDM
Lidia L. Fonseca Executive VP, Chief Technology & Digital Officer
Douglas M. Lankler Executive Vice President & General Counsel
James Quincey Independent Director
Scott Gottlieb Independent Director
Suzanne Nora Johnson Independent Director
Helen H. Hobbs Independent Director
James C. Smith Independent Director
Susan J. Hockfield Independent Director
Susan D. Desmond-Hellmann Independent Director
Ronald Edward Blaylock Independent Director
Dan R. Littman Independent Director
Joseph J. Echevarria Independent Director
Shantanu Narayen Lead Independent Director
Suneet Varma President-US Oncology Business Unit
William C. Sessa SVP &Chief Scientific Officer-Internal Medicine
Annaliesa Anderson SVP, Head-Vaccine Research & Development
Margaret M. Madden Secretary, Chief Governance Counsel & Senior VP
Jennifer B. Damico Senior Vice President & Controller
Bryan Supran Senior Vice President & Deputy General Counsel
Gordon Loh Senior Vice President-Corporate Audit
Markus Green Vice President & Assistant General Counsel
John DeYoung Vice President-Worldwide Business Development
Barbara J. Dalton Vice President-Worldwide Business Development